arrow
H

Hao-Wen Sim

Chris O'Brien Lifehouse
H指数:19
被引数:1,563

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

GUARD-LGG: a glioma upfront AI-driven radiotherapy response decipher for lower-grade glioma

GUARD-LGG: 针对低级别神经胶质瘤的神经胶质瘤前期AI驱动的放射治疗反应破译

2026-10-200
OAAI
PATH-18. Investigating the role of CDKN2A loss in IDH-mutant gliomas: biological insights beyond tumour grading

PATH-18. 研究CDKN2A缺失在IDH突变型胶质瘤中的作用:超越肿瘤分级的生物学见解

2025-11-110
OA
INTERROGATE-GBM Phase I trial: Immunotherapy peptide vaccine targeting cytomegalovirus (CMV) antigens in glioblastoma

INTERROGATE-GBM Ⅰ期临床试验:针对巨细胞病毒(CMV)抗原的胶质母细胞瘤免疫治疗肽疫苗

2025-11-010
OAAI
Low and Intermediate Grade Glioma Umbrella Study of Molecular Guided TherapieS (LUMOS2) study

低级别和间级别胶质瘤伞式研究:分子指导疗法(LUMOS2)研究

2025-11-010
OAAI
Real-world clinical outcomes of oligometastatic prostate cancer using SBRT: An Australian experience

寡转移性前列腺癌的立体定向放射治疗(SBRT)真实世界临床疗效:澳大利亚经验

2025-10-010
OAAI
Temporally resolved proteomics identifies nidogen-2 as a cotarget in pancreatic cancer that modulates fibrosis and therapy response

暂时分辨的蛋白质组学将nidogen-2鉴定为胰腺癌的共靶标,其调节纤维化和治疗反应

2024-07-052
OAAI
Plasma Cetuximab Concentrations Correlate With Survival in Patients With Advanced KRAS Wild Type Colorectal Cancer
2023-12-010
OAAI
NUTMEG: A randomized phase II study of nivolumab and temozolomide versus temozolomide alone in newly diagnosed older patients with glioblastoma

肉豆蔻: nivolumab和替莫唑胺与替莫唑胺单独治疗新诊断的老年胶质母细胞瘤患者的随机II期研究

2023-09-227
OAAI
BRAF-mediated brain tumors in adults and children: A review and the Australian and New Zealand experience
2023-04-145
OAAI